You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Potential Impact of Amyloid Imaging on Diagnosis and Intended Management in Patients With Progressive Cognitive Decline
|
|---|---|
| Published in |
Alzheimer Disease & Associated Disorders, January 2013
|
| DOI | 10.1097/wad.0b013e318279d02a |
| Pubmed ID | |
| Authors |
Michael Grundman, Michael J. Pontecorvo, Stephen P. Salloway, P. Murali Doraiswamy, Adam S. Fleisher, Carl H. Sadowsky, Anil K. Nair, Andrew Siderowf, Ming Lu, Anupa K. Arora, Abigail Agbulos, Matthew L. Flitter, Michael J. Krautkramer, Khaled Sarsour, Daniel M. Skovronsky, Mark A. Mintun |
| Abstract |
Florbetapir F18 has been approved by the Food and Drug Administration for in vivo assessment of amyloid pathology in patients undergoing evaluation for Alzheimer disease (AD). The aim of this study was to determine the impact of amyloid imaging on the diagnoses and management of patients undergoing evaluation for cognitive decline. Patients were recruited to participate at 19 clinical sites. The site physician provided a provisional diagnosis, an estimate of their diagnostic confidence, and their plan for diagnostic evaluation and management both before and after receiving the results from amyloid imaging with florbetapir F18. Analyses compared the frequency of AD and non-AD diagnoses, plans for ancillary testing, and intended patient management before and after florbetapir imaging. A total of 229 patients participated in the trial (113 amyloid positive, 116 amyloid negative). After receiving the results of the florbetapir scan, diagnosis changed in 125/229, or 54.6% [95% confidence intervals (CI), 48.1%-60.9%], of cases, and diagnostic confidence increased by an average of 21.6% (95% CI, 18.3%-24.8%). A total of 199/229 or 86.9% (95% CI, 81.9%-90.7%) of cases had at least 1 change in their management plan. Intended cholinesterase inhibitor or memantine treatment increased by 17.7% (95% CI, 11.8%-25.8%) of all cases with positive scans and decreased by 23.3% (95% CI, 16.5%-31.8%) of all those with negative scans. Among subjects who had not yet undergone a completed work up, planned brain structural imaging (computed tomographic/magnetic resonance imaging) decreased by 24.4% (95% CI, 17.5%-32.8%) and planned neuropsychological testing decreased by 32.8% (95% CI, 25.0%-41.6%). In summary, amyloid imaging results altered physician's diagnostic thinking, intended testing, and management of patients undergoing evaluation for cognitive decline. |
X Demographics
The data shown below were collected from the profiles of 5 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Argentina | 1 | 20% |
| Netherlands | 1 | 20% |
| Unknown | 3 | 60% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 5 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 104 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 2 | 2% |
| Cuba | 2 | 2% |
| Chile | 1 | <1% |
| Brazil | 1 | <1% |
| United States | 1 | <1% |
| Unknown | 97 | 93% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Other | 18 | 17% |
| Researcher | 18 | 17% |
| Student > Master | 12 | 12% |
| Student > Ph. D. Student | 7 | 7% |
| Student > Bachelor | 7 | 7% |
| Other | 17 | 16% |
| Unknown | 25 | 24% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 35 | 34% |
| Neuroscience | 9 | 9% |
| Psychology | 6 | 6% |
| Agricultural and Biological Sciences | 4 | 4% |
| Engineering | 3 | 3% |
| Other | 16 | 15% |
| Unknown | 31 | 30% |
Attention Score in Context
This research output has an Altmetric Attention Score of 24. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 27 August 2015.
All research outputs
#1,568,539
of 25,371,288 outputs
Outputs from Alzheimer Disease & Associated Disorders
#37
of 991 outputs
Outputs of similar age
#13,764
of 288,986 outputs
Outputs of similar age from Alzheimer Disease & Associated Disorders
#1
of 15 outputs
Altmetric has tracked 25,371,288 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 93rd percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 991 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 9.2. This one has done particularly well, scoring higher than 96% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 288,986 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 95% of its contemporaries.
We're also able to compare this research output to 15 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 93% of its contemporaries.